Equity Profile

BIO

Bio-Rad Laboratories, Inc.

Health CareLife Sciences Tools & Services$7.8B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Bio-Rad Laboratories, Inc. is a key player in the health care sector, specializing in life sciences tools and services....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a crucial indicator of a company's profitability and is closely watched by investors.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and is vital for assessing overall performance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BIO Q2-2026 Earnings Preview

Context

Company Snapshot

Bio-Rad Laboratories, Inc. is a key player in the health care sector, specializing in life sciences tools and services. The company provides essential products for research and clinical diagnostics, making it significant in the ongoing advancements in health care and biotechnology.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+15.34%

Avg Stock Reaction

-1.01%

Last Quarter Recap

In Q1-2026, Bio-Rad reported an EPS of $1.89, missing estimates by 31.77%. The stock reacted positively, gaining 1.81% the following day despite the miss.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of Bio-Rad's Q2-2026 earnings report, especially after the significant EPS miss last quarter. The lack of analyst estimates adds uncertainty to expectations.

Bull Case

If Bio-Rad can demonstrate strong revenue growth and improve its EPS, it could regain investor confidence and see a positive stock reaction.

Bear Case

Continued misses on earnings and revenue could lead to further declines in stock price, especially given the current market volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the significant miss last quarter, investors will closely watch EPS to gauge if the company can recover and meet expectations.

What is the revenue growth rate for this quarter?

Revenue growth is critical for assessing the company's market position and overall health, especially after recent performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Bio-Rad's ability to rebound from its recent earnings miss, particularly given the potential for improved operational efficiencies.

Supporting Evidence

The options market is pricing a 17.11% move, suggesting that investors expect significant volatility, which could indicate a potential surprise.

Historical patterns show that the stock has reacted positively to earnings beats, even if the overall trend has been mixed.

Key Risk

If the EPS comes in above $2.50, it could shift sentiment dramatically and challenge the current bearish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Bio-Rad can bounce back from recent earnings misses and demonstrate solid growth.

Bull Confirmed If

An EPS of $2.50 or higher would confirm a strong recovery and positive sentiment.

Bear Confirmed If

An EPS below $1.80 would signal ongoing struggles and could lead to a further decline in stock price.

Pre-Earnings Positioning

Options Market

Implied Move

±17.11%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a significant move, indicating heightened uncertainty around the earnings report.

Options are pricing ±17.1% while BIO has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

58.0%

Calls (2K)P/C Ratio: 0.33Puts (400)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bio-Rad beats expectations, history suggests a potential stock increase of around 1.67%, confirming a positive turnaround.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline of approximately 0.97%, reinforcing concerns about the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific guidance on revenue growth for the upcoming quarters.
2Management's commentary on operational efficiencies and cost management.
3Updates on new product launches or innovations in their life sciences tools.
4Insights into market demand and competitive positioning.
5Any changes in strategic direction or focus areas for the company.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

KRCAMC

Kilroy Realty Corporation

PreviewView

Jul27

PIIAMC

Company Snapshot

Bio-Rad Laboratories, Inc. is a key player in the health care sector, specializing in life sciences tools and services....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a crucial indicator of a company's profitability and is closely watched by investors.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and is vital for assessing overall performance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BIO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+15.34%

Avg Stock Reaction

-1.01%

Last Quarter Recap

In Q1-2026, Bio-Rad reported an EPS of $1.89, missing estimates by 31.77%. The stock reacted positively, gaining 1.81% the following day despite the miss.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of Bio-Rad's Q2-2026 earnings report, especially after the significant EPS miss last quarter. The lack of analyst estimates adds uncertainty to expectations.

Bull Case

If Bio-Rad can demonstrate strong revenue growth and improve its EPS, it could regain investor confidence and see a positive stock reaction.

Bear Case

Continued misses on earnings and revenue could lead to further declines in stock price, especially given the current market volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the significant miss last quarter, investors will closely watch EPS to gauge if the company can recover and meet expectations.

What is the revenue growth rate for this quarter?

Revenue growth is critical for assessing the company's market position and overall health, especially after recent performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Bio-Rad's ability to rebound from its recent earnings miss, particularly given the potential for improved operational efficiencies.

Supporting Evidence

The options market is pricing a 17.11% move, suggesting that investors expect significant volatility, which could indicate a potential surprise.

Historical patterns show that the stock has reacted positively to earnings beats, even if the overall trend has been mixed.

Key Risk

If the EPS comes in above $2.50, it could shift sentiment dramatically and challenge the current bearish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Bio-Rad can bounce back from recent earnings misses and demonstrate solid growth.

Bull Confirmed If

An EPS of $2.50 or higher would confirm a strong recovery and positive sentiment.

Bear Confirmed If

An EPS below $1.80 would signal ongoing struggles and could lead to a further decline in stock price.

Pre-Earnings Positioning

Options Market

Implied Move

±17.11%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a significant move, indicating heightened uncertainty around the earnings report.

Options are pricing ±17.1% while BIO has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

58.0%

Calls (2K)P/C Ratio: 0.33Puts (400)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bio-Rad beats expectations, history suggests a potential stock increase of around 1.67%, confirming a positive turnaround.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline of approximately 0.97%, reinforcing concerns about the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific guidance on revenue growth for the upcoming quarters.
2Management's commentary on operational efficiencies and cost management.
3Updates on new product launches or innovations in their life sciences tools.
4Insights into market demand and competitive positioning.
5Any changes in strategic direction or focus areas for the company.